Form 4 for INMB Inmune Bio, Inc.
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001213900-22-014507 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-23 | 2022-03-22 | INMB | Tesi Raymond Joseph | Pres, CEO, Dir, 10% | A - Grant | $8.43 | +23.7K | 1.51M | +2% | +$200.0K |
| D | 2022-03-23 | 2022-03-21 | INMB | Tesi Raymond Joseph | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +130.0K | 130.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-22 | A | A | 23,724 | $8.43 | 1,514,398 | D | — | — | (F1) The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities . These shares were purchased by the Reporting Person directly from Issuer. |
| 2 | Derivative | Option (right to buy) | 2022-03-21 | A | A | 130,000 | $0.00 | 130,000 | D | $7.92 · — to 2032-03-20 | 130,000 Common Stock | (F2) Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date. |